StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 8 sell-side ratings as of 2023-02-01. Stonvex does not endorse these ratings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Next report date, year-over-year trend, and recent quarter history.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.69 | $0.68 | -1.35% | 0.0M |
| 05-19 | $1.79 | $1.60 | -10.61% | 93.1M |
| 05-20 | $1.49 | $1.61 | +8.05% | 3.4M |
| 05-21 | $1.55 | $1.73 | +11.61% | 2.1M |
| 05-22 | $1.77 | $1.72 | -2.82% | 0.7M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows INM's percentile within the scored universe — observational ranking, not a recommendation.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2022 2022-06-30 | Q1 2022 2022-03-31 | Q4 2021 2021-12-31 | Annual 2021 2021-06-30 |
|---|---|---|---|---|
Revenue | $1.37M | $574.68K | $265.09K | $1.90M |
Operating Income | $-18.60M | $-10.73M | $-7.25M | $-10.20M |
Net Income | $-18.60M | $-10.73M | $-7.25M | $-10.20M |
EPS (Diluted) | $-33.17 | $-20.13 | $-14.03 | $-37.96 |
Total Assets | $12.79M | $15.49M | $19.38M | $9.78M |
Total Liabilities | $3.71M | $4.60M | $5.22M | $2.40M |
Cash & Equivalents | $6.18M | $5.90M | $11.28M | $7.36M |
Free Cash Flow OCF − CapEx | $-15.62M | $-11.58M | $-6.22M | $-9.79M |
Shares Outstanding | 650.67K | 14.28M | 14.14M | 322.03K |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.